Die anti-tumorale Wirkung des neuen Phosphoinositid-3-Kinase-Inhibitors BAY 80-6946  auf humane Myelom-Zellen

Hensen, Janina

dc.contributor.advisor	Schön, Margarete Prof. Dr.
dc.contributor.author	Hensen, Janina
dc.date.accessioned	2015-01-12T08:19:47Z
dc.date.available	2015-01-30T23:50:05Z
dc.date.issued	2015-01-12
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-0023-997D-4
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-4848
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-4848
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.ddc	610	de
dc.title	Die anti-tumorale Wirkung des neuen Phosphoinositid-3-Kinase-Inhibitors BAY 80-6946 auf humane Myelom-Zellen	de
dc.type	doctoralThesis	de
dc.title.translated	The anti-tumour activity of the novel PI3K inhibitor BAY 80-6946 on myeloma cells	de
dc.contributor.referee	Schön, Michael P. Prof. Dr.
dc.date.examination	2015-01-20
dc.description.abstracteng	Overcoming drug resistance in the bone marrow microenvironment is an unresolved challenge in therapy of multiple myeloma. Despite numerous therapeutic approaches with new agents targeting the bone marrow microenvironment multiple myeloma still remains an incurable condition. Multiple myeloma cells exhibit numerous mechanisms of drug resistance. Constitutive activation of the Phosphatidylinositol-3-kinase (PI3K) is associated with tumour progression in multiple myeloma. Targeting the PI3K/Akt pathway can induce apoptosis in multiple myeloma cells. Therefore the use of PI3K inhibitors is predicted to increase the susceptibility of myeloma cells to anticancer therapy. We investigated the novel selective PI3K inhibitor BAY 80-6946 in four human myeloma cell lines. BAY 80-6946 induced significant inhibition of Akt phosphorylation in a dose-dependent manner being accompanied with an increase of apoptosis and inhibition of cell cycle progression. Moreover BAY 80-6946 could overcome the stimulation conferred by insulin-like growth-factor-1 (IGF-1). In addition, BAY 80-6946 showed in vivo activity against two human myeloma cell lines in a preclinical murine Xenograft model.	de
dc.contributor.coReferee	Bastians, Holger Prof. Dr.
dc.contributor.thirdReferee	Oppermann, Martin Prof. Dr.
dc.subject.ger	Multiples Myelom	de
dc.subject.ger	Medikamentenresistenz	de
dc.subject.ger	PI3-Kinase	de
dc.subject.eng	myeloma	de
dc.subject.eng	chemoresistance	de
dc.subject.eng	PI3 kinase	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-0023-997D-4-2
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Medizin (PPN619874732)	de
dc.subject.gokfull	Innere Medizin - Allgemein- und Gesamtdarstellungen (PPN619875747)	de
dc.description.embargoed	2015-01-30
dc.identifier.ppn	81525668X

Dateien

Name:Hensen_Janina_Dissertation.pdf

Größe:1.898Mb

Format:PDF

Öffnen

Name:: Hensen_Janina_Dissertation.pdf
Größe:: 1.898Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2872]

Zur Kurzanzeige